GUSKA
Turning viruses into anti-cancer nanoweapons
Improving the lives of cancer patients through synthetic RNA viral technologies
Guska uses oncolytic viruses to develop treatments that can specifically target cancer cells without harming healthy ones.
Board
Nicolás Tambucho - CEO
Biotechnology Engineer (ORT University)
Gonzalo Moratorio - Founder
Virologist (PostDoc training at the Virology Department of the Institut Pasteur Paris); PhD in Molecular and Cellular Biology (IP Montevideo and Udelar)
Pilar Moreno - Co-founder
PhD in Molecular and Cellular Biology; Biochemist (IP Montevideo and Udelar)